(S)-(−)-N-Acetyl-leucine
| |
Names | |
---|---|
IUPAC name
2-Acetamido-4-methylpentanoic acid
[1]
| |
Other names
N-Acetylleucine; N-Acetyl-L-Leucine
| |
Identifiers | |
| |
3D model (
JSmol)
|
|
3DMet |
|
1724849 (S)-(−) | |
ChEBI |
|
ChEMBL |
|
ChemSpider | |
EC Number |
|
985259 (S)-(−) | |
KEGG |
|
MeSH | acetylleucine |
PubChem
CID
|
|
UNII |
|
| |
| |
Properties | |
C8H15NO3 | |
Molar mass | 173.212 g·mol−1 |
Appearance | White crystals |
Melting point | −115 to −113 °C; −175 to −172 °F; 158 to 160 K |
log P | −0.265 |
Acidity (pKa) | 3.666 |
Basicity (pKb) | 10.331 |
Pharmacology | |
N07CA04 ( WHO) | |
Related compounds | |
Related compounds
|
ENU |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
Acetylleucine is a modified amino acid used in the treatment of vertigo [2] and cerebellar ataxia.
Acetylleucine is also being developed as a possible treatment for several neurological disorders by IntraBio Inc. [3] Clinical trials with acetylleucine for the treatment of three orphan, fatal, neurodegenerative disorders are underway: Niemann-Pick disease type C, [4] GM2 gangliosidoses ( Tay-Sachs and Sandhoff diseases), [5] and ataxia–telangiectasia. [6] In 2020, IntraBio announced the successful multinational clinical trial results of the Niemann-Pick type C clinical trial. [7] IntraBio is also investigating acetylleucine for the treatment of common inherited and acquired neurological diseases including Lewy body dementia, [8] amyotrophic lateral sclerosis, restless legs syndrome, multiple sclerosis, and migraine [9] Acetylleucine has received orphan drug designations from the U.S. Food & Drug Administration (FDA) [10] [11] [12] [13] and the European Commission. [14] [15] [16] [17]
{{
cite journal}}
: Cite journal requires |journal=
(
help)
(S)-(−)-N-Acetyl-leucine
| |
Names | |
---|---|
IUPAC name
2-Acetamido-4-methylpentanoic acid
[1]
| |
Other names
N-Acetylleucine; N-Acetyl-L-Leucine
| |
Identifiers | |
| |
3D model (
JSmol)
|
|
3DMet |
|
1724849 (S)-(−) | |
ChEBI |
|
ChEMBL |
|
ChemSpider | |
EC Number |
|
985259 (S)-(−) | |
KEGG |
|
MeSH | acetylleucine |
PubChem
CID
|
|
UNII |
|
| |
| |
Properties | |
C8H15NO3 | |
Molar mass | 173.212 g·mol−1 |
Appearance | White crystals |
Melting point | −115 to −113 °C; −175 to −172 °F; 158 to 160 K |
log P | −0.265 |
Acidity (pKa) | 3.666 |
Basicity (pKb) | 10.331 |
Pharmacology | |
N07CA04 ( WHO) | |
Related compounds | |
Related compounds
|
ENU |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
Acetylleucine is a modified amino acid used in the treatment of vertigo [2] and cerebellar ataxia.
Acetylleucine is also being developed as a possible treatment for several neurological disorders by IntraBio Inc. [3] Clinical trials with acetylleucine for the treatment of three orphan, fatal, neurodegenerative disorders are underway: Niemann-Pick disease type C, [4] GM2 gangliosidoses ( Tay-Sachs and Sandhoff diseases), [5] and ataxia–telangiectasia. [6] In 2020, IntraBio announced the successful multinational clinical trial results of the Niemann-Pick type C clinical trial. [7] IntraBio is also investigating acetylleucine for the treatment of common inherited and acquired neurological diseases including Lewy body dementia, [8] amyotrophic lateral sclerosis, restless legs syndrome, multiple sclerosis, and migraine [9] Acetylleucine has received orphan drug designations from the U.S. Food & Drug Administration (FDA) [10] [11] [12] [13] and the European Commission. [14] [15] [16] [17]
{{
cite journal}}
: Cite journal requires |journal=
(
help)